Abstract
The inactivatedsevere acute respiratory syndrome coronavirus 2 vaccine (CoronaVac) has been the principal vaccine used in Chile's prebooster immunization campaign. We compared major outcomes in 206 hospitalized vaccinated adults vs 507 unvaccinated adults (mid-2021). Individuals in the vaccinated group were much older, required less critical care, had lower mortality (adjusted by age), and had shorter hospitalization than those in the unvaccinated group. Benefits were most pronounced in those ≥60years of age.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have